Human amnion cells reverse acute and chronic pulmonary damage in experimental neonatal lung injury.
Model: Bronchopulmonary dysplasia model combining intra-amniotic lipopolysaccharide 0.1 ug in 5 ul per sac at embryonic day 16 with postnatal hyperoxia at FiO2 0.65 begun within 12 h of birth or at postnatal day 3.5, for 7, 14 or 28 days
A single dose of human amnion epithelial cells improved lung tissue-to-airspace ratio dose-dependently, with 75,000 and 100,000 cells effective by postnatal day 7, and intravenous and intratracheal routes were equally efficacious. Early and late treatment both restored septal crest density, lowered…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.